You searched for "registrars"

474 results found

Fusion Bx 2.0 targeted prostate biopsy solution receives CE Mark

Focal Healthcare, an innovator of image-guided prostate cancer technology, has received CE Mark for its Fusion BxTM 2.0 prostate fusion biopsy solution.

So you want to go on a Fellowship: part 1

Look out for part 2 of this series later in 2016 when the author will discuss settling into the research role of his fellowship and will reflect on his first year overseas. This is the first in a series of...

Technology for remote working and COVID-19 resources

The COVID-19 pandemic has altered every aspect of how we live, and how healthcare needs to be provided for the welfare of patients and staff. I thought I would try to summarise a few potential technology tools that could be...

MOOCs

Technology has always been intimately linked to new educational methods. This has included distance learning, learning through multimedia and finally computer-based learning. Massive Open Online Courses (MOOCs) are so called because they can be taken by an unlimited number of...

Frequency-volume chart apps for nocturia: keeping urologists up at night

Background Nocturia is a bothersome symptom and the leading cause of disturbed sleep in adults. It is extremely common, with 55% of men and 60% of women aged 50 waking at least once in the night, with a further 20%...

Post-Brexit deal welcomed but leaves future relationship with EU far from settled

This article was originally published EYE NEWS VOLUME 27 ISSUE 6 APRIL/MAY 2021 Rod McNeil breaks down the impact of the Brexit deal on healthcare in the UK, including medicines regulation, research funding, sharing of information and the ability to...

Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel

This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...

New drug hope for prostate cancer patients

• Hormone therapy is used to slow the progression of advanced prostate cancer, but cancers often develop resistance and continue to grow.• Research reveals that patients with higher levels of heat shock proteins have worse outcomes.• Targeting these proteins with...

How do we tackle social injustice in urological cancer?

Socioeconomic status as an established determinant of health and associated injustices is well recognised. Confronting these injustices and creating a fairer healthcare system is an ongoing challenge for many governments. In Scotland, the devolved government has created the Scottish Index...

An update on lower pole stone management for 2015

Introduction Urolithiasis is an increasing healthcare problem, with an estimated lifetime prevalence of up to 15% [1]. The number of interventions undertaken for stone disease has increased dramatically over recent years, particularly with respect to ureteroscopy and percutaneous nephrolithotomy (PCNL)...

An update on antibiotic prophylaxis in TRUS-guided prostate biopsy

Since its inception in the 1980s, transrectal ultrasound (TRUS)-guided prostate biopsy has remained the standard tool for the histological diagnosis of prostate cancer. There are several advantages to this technique which have led to the widespread use of TRUS in...

In conversation with Professor Christopher Chapple

Professor Christopher Chappel. Prof Chapple, thank you for taking the time to chat with the Urology News team. Can we start by asking about your background and how you ended up in the field of urology? Early in my career...